Aligned Genetics Inc Cash Flow Conversion Efficiency
Aligned Genetics Inc cash flow conversion efficiency. Based on the latest financial reports, Aligned Genetics Inc (238120) has a cash flow conversion efficiency ratio of -0.058x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.04 Billion ≈ $-1.38 Million USD) by net assets (₩35.50 Billion ≈ $24.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aligned Genetics Inc (2015–2024)
Cash flow conversion efficiency of Aligned Genetics Inc from 2015 to 2024. This chart illustrates how Aligned Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Aligned Genetics Inc share price for real-time trading data and today's change.
Aligned Genetics Inc Cash Flow Conversion Ratio Explained
Aligned Genetics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aligned Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aligned Genetics Inc ranked by their cash flow conversion efficiency. Also see 238120 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Blaize Holdings, Inc.
NASDAQ:BZAI
|
-19.079x |
|
Pamapol S.A.
WAR:PMP
|
-0.041x |
|
Boundless Bio, Inc. Common Stock
NASDAQ:BOLD
|
-0.093x |
|
Myungmoon Phar
KO:017180
|
0.005x |
|
Ovaro Kiinteistosijoitus Oyj
HE:OVARO
|
-0.048x |
|
Latrobe Magnesium Limited
F:L2Q
|
0.064x |
|
Archtis Ltd
AU:AR9
|
-0.252x |
|
PESTECH International Bhd
KLSE:5219
|
-0.161x |
Annual Cash Flow Conversion Efficiency for Aligned Genetics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Aligned Genetics Inc from 2015 to 2024. Review free cash flow generation of Aligned Genetics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩35.49 Billion ≈ $24.05 Million |
₩3.07 Billion ≈ $2.08 Million |
0.086x | -5.07% |
| 2023-12-31 | ₩31.31 Billion ≈ $21.22 Million |
₩2.85 Billion ≈ $1.93 Million |
0.091x | +18.10% |
| 2022-12-31 | ₩28.85 Billion ≈ $19.55 Million |
₩2.22 Billion ≈ $1.51 Million |
0.077x | +1429.28% |
| 2021-12-31 | ₩26.99 Billion ≈ $18.29 Million |
₩135.97 Million ≈ $92.14K |
0.005x | +203.10% |
| 2020-12-31 | ₩21.46 Billion ≈ $14.55 Million |
₩35.67 Million ≈ $24.17K |
0.002x | -94.71% |
| 2019-12-31 | ₩20.97 Billion ≈ $14.21 Million |
₩659.29 Million ≈ $446.79K |
0.031x | +137.58% |
| 2018-12-31 | ₩20.89 Billion ≈ $14.16 Million |
₩-1.75 Billion ≈ $-1.18 Million |
-0.084x | -116.08% |
| 2017-12-31 | ₩22.64 Billion ≈ $15.34 Million |
₩-876.75 Million ≈ $-594.16K |
-0.039x | +17.86% |
| 2016-12-31 | ₩24.18 Billion ≈ $16.39 Million |
₩-1.14 Billion ≈ $-772.65K |
-0.047x | +18.73% |
| 2015-12-31 | ₩6.06 Billion ≈ $4.11 Million |
₩-351.72 Million ≈ $-238.36K |
-0.058x | -- |
About Aligned Genetics Inc
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genet… Read more